LTRN Lantern Pharma Inc.

Price Chart

Executive Summary

Lantern Pharma entered into a securities purchase agreement to raise approximately $4.4 million through the sale of shares and warrants at $2.06 per share, alongside pre-funded warrants and 5-year warrants exercisable at $2.27. The proceeds are earmarked for working capital and to fund the spin-off of its 'withZeta' AI platform into a new subsidiary (NewCo), with a target for NewCo's public emergence within one year. This dilutive capital raise, occurring simultaneously with a prior 424B5 offering, signals acute cash needs and adds significant warrant overhang, outweighing the strategic value of the withZeta spin-off.

Key Financial Metrics

Actionable Insight

Key Facts

• Raised approximately $4.4 million via a registered direct offering and concurrent private placement of warrants.
• Issued shares and pre-funded warrants at $2.06 per share, with 5-year warrants exercisable at $2.27 per share.
• Investors received warrants to purchase up to 100% of the number of shares/pre-funded warrant shares purchased.
• Proceeds will be used for working capital and to fund the formation and public emergence of 'NewCo', a subsidiary housing the withZeta AI platform.
• The company must form NewCo by July 31, 2026, and use commercially reasonable efforts to achieve NewCo's public emergence within one year.
• This offering follows a dilutive 424B5 offering filed on May 14, 2026, which raised approximately $3.94 million.
• The company has a going-concern risk and requires substantial additional funding, as disclosed in the prior 424B5 filing.
• Insiders have purchased $200K in stock over the past 30 days, a small amount relative to the $4.4M raise.
• The company has a $28M market cap; the combined ~$8.3M in recent capital raises represents roughly 30% of market cap.

Financial Impact

Immediate dilution of approximately 19% from the prior 424B5 offering, plus additional dilution from this $4.4M offering. The combined dilution from both offerings is significant for a $28M market cap company. The warrants represent a 100% overhang on the shares sold, exercisable at $2.27, creating future dilution risk.

Risk Factors

• Substantial dilution from the combined $8.3M in recent offerings and the 100% warrant overhang.
• Failure to achieve NewCo public emergence within one year triggers a more onerous participation right for investors.
• Going-concern risk remains, as the company needs substantial additional funding beyond these raises.
• Potential Nasdaq delisting if the stock price continues to decline.
• The spin-off of withZeta may not create shareholder value and could be a distraction.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status